South Korea in talks to secure 40 million doses of Novavax’s COVID-19 vaccine
South Korea is in talks to purchase 40 million doses of a coronavirus vaccine developed by Novavax, its local manufacturer SK bioscience said on Wednesday.
Related Articles
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
The U.S. Food and Drug Administration approved Pfizer’s gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that…
CVS Omnicare staff in Las Vegas vote to join new union
Staff at CVS Health’s unit Omnicare in Las Vegas voted to join the Pharmacy Guild, becoming the first location at the national pharmacy chain to…
Centene’s concerns over Medicare market dull Q1 profit beat
Centene said on Friday its Medicare insurance business would face several challenges next year, taking the sheen off a strong first-quarter earnings report from the…
Bayer CEO wins first AGM shareholder vote
Bayer CEO Bill Anderson on Friday won a vote of confidence at his first annual general meeting (AGM) at the helm of the embattled healthcare…
Bayer CEO wins first AGM shareholder vote
Bayer CEO Bill Anderson on Friday won a vote of confidence at his first annual general meeting (AGM) at the helm of the embattled healthcare…
HCA’s unchanged annual forecast clouds better-than-expected quarter
HCA Healthcare on Friday beat Wall Street estimates for quarterly profit and revenue but left its annual forecast unchanged, sending shares of the largest for-profit…
Drugmaker AbbVie expects Humira volume erosion to worsen
AbbVie expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S. pharmacy benefit managers and as…
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
The U.S. Food and Drug Administration approved Pfizer’s gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that…
Centene sees robust 2024 on commercial insurance business boost
Centene Corp raised its annual profit forecast and beat Wall Street estimates for first-quarter profit on Friday, as higher premiums from commercial insurance plans helped…
Bayer investor Deka takes a stand against CEO in annual vote
Bayer shareholder Deka Investment said on Friday it would not join other large investors in supporting the healthcare and agriculture group’s management at its annual…